Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 110 (7), 1321-6

The Incidence of Irreversible Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Reappraisal

Affiliations

The Incidence of Irreversible Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Reappraisal

Ioannis Mavrikakis et al. Ophthalmology.

Abstract

Purpose: To define the risk of hydroxychloroquine (HCQ)-related retinal toxicity in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) who are receiving recommended dosages of the drug (< or =6.5 mg/kg/day).

Design: Prospective cohort study, from 1985 to 2000.

Participants: Greek patients with RA (n = 335) and SLE (n = 191) treated with HCQ, 400 of whom had completed at least 6 years of treatment.

Methods: Ophthalmologic evaluation was performed every 6 months from 1985 to 1995, and yearly thereafter. This consisted of best-corrected visual acuity, color vision testing, static central visual field testing, fundoscopy, electroretinography, and fluorescein angiography, when indicated.

Main outcome measures: Fundus lesions attributed to HCQ.

Results: No HCQ retinal toxicity was noted in any of the 526 patients during the first 6 years of treatment. Two (3.4%) of the first 58 long-term (>6 years) treated patients developed HCQ-related maculopathy at 8 and 6.5 years of treatment, despite regular ophthalmologic evaluation. On follow-up 7 and 9 years after cessation of HCQ treatment, both patients had stable eye disease. No HCQ retinal toxicity was observed in the subsequent 342 patients who were treated for >6 years. Overall, the incidence of HCQ-related retinopathy in 400 patients who were treated with recommended dosages of the drug for a mean of 8.7 years was reduced to 0.5%.

Conclusions: After a baseline ophthalmic examination to confirm the absence of preexisting fundus pathology, patients with normal renal function may receive HCQ at a maximal daily dosage of 6.5 mg/kg and continue safely for 6 years. However, annual screening is recommended in patients who have taken the drug, even in recommended doses, for >6 years.

Similar articles

See all similar articles

Cited by 50 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback